Status:
COMPLETED
A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults
Lead Sponsor:
Pfizer
Conditions:
Schizophrenia
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 14 days of treatment with PF-05180999 in healthy subjects.
Eligibility Criteria
Inclusion
- male or female of non-childbearing potential,
Exclusion
- Evidence of clinically significant medical illness, history of seizures, any condition possibly affecting drug absorption
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT01429740
Start Date
August 1 2011
End Date
December 1 2011
Last Update
April 12 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511